Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.

Elizabeth Poplin; Harpreet Wasan; Lindsey Rolfe; Mitch Raponi; Tone Ikdahl; Ihor Bondarenko; Irina Davidenko; Volodymyr Bondar; August Garin; Stefan Boeck; Steffen Ormanns; Volker Heinemann; Claudio Bassi; T R Jeffrey Evans; Roland Andersson; Hejin Hahn; Vince Picozzi; Adam Dicker; Elaina Mann; Cynthia Voong; Paramjit Kaur; Jeff Isaacson; Andrew Allen

doi:10.1200/JCO.2013.51.0826

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.

Elizabeth Poplin, Harpreet Wasan, Lindsey Rolfe, Mitch Raponi, Tone Ikdahl, Ihor Bondarenko, Irina Davidenko, Volodymyr Bondar, August Garin, Stefan Boeck, Steffen Ormanns, Volker Heinemann, Claudio Bassi, T R Jeffrey Evans, Roland Andersson, Hejin Hahn, Vince Picozzi, Adam Dicker, Elaina Mann, Cynthia VoongParamjit Kaur, Jeff Isaacson, Andrew Allen

Surgery (Lund)

Research output: Contribution to journal › Article › peer-review

Abstract

Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression.

Original language	English
Pages (from-to)	4453-4461
Journal	Journal of Clinical Oncology
Volume	31
Issue number	35
DOIs	https://doi.org/10.1200/JCO.2013.51.0826
Publication status	Published - 2013

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2013.51.0826

http://www.ncbi.nlm.nih.gov/pubmed/24220555?dopt=Abstract

Fingerprint

Dive into the research topics of 'Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.'. Together they form a unique fingerprint.

Cite this

Poplin, E., Wasan, H., Rolfe, L., Raponi, M., Ikdahl, T., Bondarenko, I., Davidenko, I., Bondar, V., Garin, A., Boeck, S., Ormanns, S., Heinemann, V., Bassi, C., Evans, T. R. J., Andersson, R., Hahn, H., Picozzi, V., Dicker, A., Mann, E., ... Allen, A. (2013). Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. Journal of Clinical Oncology, 31(35), 4453-4461. https://doi.org/10.1200/JCO.2013.51.0826

@article{9d49128d481e4770b1904102eca35e30,

title = "Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.",

abstract = "Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression.",

author = "Elizabeth Poplin and Harpreet Wasan and Lindsey Rolfe and Mitch Raponi and Tone Ikdahl and Ihor Bondarenko and Irina Davidenko and Volodymyr Bondar and August Garin and Stefan Boeck and Steffen Ormanns and Volker Heinemann and Claudio Bassi and Evans, {T R Jeffrey} and Roland Andersson and Hejin Hahn and Vince Picozzi and Adam Dicker and Elaina Mann and Cynthia Voong and Paramjit Kaur and Jeff Isaacson and Andrew Allen",

year = "2013",

doi = "10.1200/JCO.2013.51.0826",

language = "English",

volume = "31",

pages = "4453--4461",

journal = "Journal of Clinical Oncology",

issn = "1527-7755",

publisher = "Lippincott Williams & Wilkins",

number = "35",

}

Poplin, E, Wasan, H, Rolfe, L, Raponi, M, Ikdahl, T, Bondarenko, I, Davidenko, I, Bondar, V, Garin, A, Boeck, S, Ormanns, S, Heinemann, V, Bassi, C, Evans, TRJ, Andersson, R, Hahn, H, Picozzi, V, Dicker, A, Mann, E, Voong, C, Kaur, P, Isaacson, J & Allen, A 2013, 'Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.', Journal of Clinical Oncology, vol. 31, no. 35, pp. 4453-4461. https://doi.org/10.1200/JCO.2013.51.0826

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. / Poplin, Elizabeth; Wasan, Harpreet; Rolfe, Lindsey et al.
In: Journal of Clinical Oncology, Vol. 31, No. 35, 2013, p. 4453-4461.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.

AU - Poplin, Elizabeth

AU - Wasan, Harpreet

AU - Rolfe, Lindsey

AU - Raponi, Mitch

AU - Ikdahl, Tone

AU - Bondarenko, Ihor

AU - Davidenko, Irina

AU - Bondar, Volodymyr

AU - Garin, August

AU - Boeck, Stefan

AU - Ormanns, Steffen

AU - Heinemann, Volker

AU - Bassi, Claudio

AU - Evans, T R Jeffrey

AU - Andersson, Roland

AU - Hahn, Hejin

AU - Picozzi, Vince

AU - Dicker, Adam

AU - Mann, Elaina

AU - Voong, Cynthia

AU - Kaur, Paramjit

AU - Isaacson, Jeff

AU - Allen, Andrew

PY - 2013

Y1 - 2013

N2 - Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression.

AB - Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression.

U2 - 10.1200/JCO.2013.51.0826

DO - 10.1200/JCO.2013.51.0826

M3 - Article

C2 - 24220555

SN - 1527-7755

VL - 31

SP - 4453

EP - 4461

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 35

ER -

Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I et al. Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. Journal of Clinical Oncology. 2013;31(35):4453-4461. doi: 10.1200/JCO.2013.51.0826